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Supplementary Figure 5. Kaplan-Meier curves for the risk of one or more islet autoantibodies (A, B), multiple islet autoantibodies (C, D), and diabetes (E, F) in GP children stratified into children with the HLA DR3/DR4-DQ8 (A, C, E) or HLA DR4-DQ8/DR4-DQ8 (B, D, F) genotypes and according to BTNL2 haplotypes. For both HLA genotypes, the 4 major BTNL2 genotypes are shown. The genotypes that include haplotype 28, which is the only BTNL2 haplotype that has the SNP rs3763305 A allele, are indicated as thick blue lines. Shaded areas represent the 95% CI. Numbers represent children at risk. P-values were calculated using log-rank tests. Figure 6 . Effect of BTNL2 knockdown in monocyte-derived dendritic cells on CD4 + T cell activation. A. Activation of isolated CD4 + CD25 -T cells by allogeneic monocyte-derived dendritic cells transfected with non-targeting siRNA or BTNL2 targeting siRNA in mixed lymphocyte cultures. CD71 expression, previously reported as a marker of allo-reactive T cell activation, was used to measure the activation of the CD4 + T cells. Dendritic cells were transfected as previously described (1) . The upper panels are exemplary FACS plots for 42 hour cultures of CD4 + T cells only and in the presence of allo-reactive transfected dendritic cells. The lower graph indicates the mean frequency CD71 + CD45RA + CD4 + T cells at the end of the 42 hour culture (4 replicates) after subtraction of the mean frequency of CD71 + CD45RA + CD4 + T cells in quadruplicate cultures without dendritic cells. Each of three dendritic cell samples was tested against two different allogeneic CD4 + T cell preparation yielding 6 data sets. Activation was increased when CD4 + T cells were activated with dendritic cells transfected with BTNL2-targeting siRNA as compared to non-targeting siRNA (p=0.031, Wilcoxon matched pair sign test). B. Activation of isolated CD4 + CD25 -T cells by autologous monocyte-derived dendritic cells transfected with non-targeting siRNA or BTNL2-targeting siRNA in the presence of flu or tetanus toxoid antigen. CD69 expression was used to measure the activation of the CD4 + T cells. The upper panels are exemplary FACS plots for 42 hour cultures of CD4 + T cells plus dendritic cells in the presence and absence of flu antigen. The lower graph indicates the mean frequency CD69 + CD4 + T cells at the end of the 42 hour culture (triplicates) after subtraction of the mean frequency of CD69 + CD4 + T cells in triplicates cultures without antigen. Each of three dendritic cell samples was tested against flu and tetanus toxoid yielding 6 data sets. Activation was not different when CD4 + T cells were activated with dendritic cells transfected with BTNL2-targeting siRNA as compared to non-targeting siRNA (p=0.43, Wilcoxon matched pair sign test). C. Efficiency of knockdown with BTNL2 vs non-targeting siRNA in dendritic cells used for A and B. 200ng of RNA from siRNA transfected cells was subjected to cDNA synthesis using a mix of oligo-dT-primer and random primer with the iScript cDNA synthesis Kit (Bio-Rad) followed by pre-amplification with gene specific primers and the SsoAdvanced PreAmp Supermix (Bio-Rad). qbase+-software (Biogazelle) was used for analysis of qPCR experiments. BTNL2 expression was normalized to reference genes TELO2 and TRMT61A and the Calibrated Normalized Relative Quantities (CNRQ) relative to the treatment with non-targeting siRNA is shown (p=0.033). Figure 7 . Risk of developing islet autoantibodies and diabetes in FDR children (B, D, F) and in GP children (A, B, C) according to genetic susceptibility strata based on BTNL2 SNP rs3763305 and genetic risk score (GRS). Risks are shown for the development of one or more islet autoantibodies (A, B), multiple islet autoantibodies (C, D), and diabetes (E, F). All of the children had the DR3/DR4-DQ8 or DR4-DQ8/DR4-DQ8 genotype. Genetic susceptibility strata were defined as follows: 1. rs3763305 GG AND GRS in the upper quartile (red); 2. rs3763305 GG AND GRS in the second quartile, OR rs3763305 GA or AA AND GRS in the upper quartile (grey); 3. rs3763305 GG AND GRS in the lower 50 th centile OR rs3763305 GA or AA AND GRS in the second quartile (green); and 4. rs3763305 GA or AA AND GRS in the lower 50 th centile (blue). P-values were calculated across all strata using log-rank tests. Figure 8 . Risk of developing one or more islet autoantibodies (A, D, G, J), multiple islet autoantibodies (B, E, H, K) and diabetes (C, F, I, L) in children with a mother with T1D (red) compared with children with a father or sibling with T1D (blue). Children have been stratified by genetic risk score and HLA DRB1*04 subtype into four risk strata from highest genetic susceptibility (A, B, C), to the lowest genetic susceptibility (J, K, L). P-values were calculated using log-rank tests. The validation cohort consists of 5,025 Caucasian subjects with European decent and HLA DR3/4-DQ8 genotype according to the algorithm defined by Barker et al. (2) , which is based on the tag SNPs rs7454108 and rs2040410. Samples were genotyped on the Illumina Immunochip array and imputed to the TOPMed Reference Panel. rs3763305 was directly genotyped on the Immunochip. rs2040410, and rs7454108 were imputed with high confidence (R2>0.99). Principal components were generated by calculating PC axes in unrelated controls using a set of 83,458 LD-pruned variants and projecting the remaining samples onto this PC space. A set of 33,249 European ancestry unrelated case-control subjects were identified for analysis by comparing PCs to 1000 Genomes Phase 3 subjects (3). We ensured samples were unrelated (less than second degree relationship) using KING version 2.13 (http://people.virginia.edu/~wc9c/KING/). 5,025 of these samples have the HLA DR3/4-DQ8 genotype. Supplementary Table 4 . Haplotypes of 34 SNPs in BTNL2 and their frequencies in HLA DR3/4-DQ8 and DR4-DQ8/DR4-DQ8. SNPs in bold are those that were identified as enriched within FDR children. Haplotype ID 'X' indicates that they are not among the 30 most frequent haplotypes. frequency [%] in rs3817969  rs3129953  rs28362678  rs2076530  rs9268480  rs2076529  rs9268481  rs3129954  rs3129955  rs4248166  rs2294884  rs2294883  rs2294882  rs2294881  rs2294880  rs9268482  rs2294878  rs3817966  rs3817964  rs3817963  rs3817962  rs3763305  rs2076525  rs2076523  rs2076522  rs3793127  rs10947260  rs10947261  rs10947262  rs3806155  rs3806156  rs3806157  rs2395158  rs3763307 42.82 0.26 1.6% (0.0-4.8%) P-value † <0.0001 0.45 <0.0001 0.60 <0.0001 0.18 * High-risk DR4 was defined as DR3/DRB1*0401 or DRB1*0401-DQ8/DR4 without 0404 or 0407, and low risk were all other genotypes; † P-values were calculated as logrank tests per column over the four strata. GRS, genetic risk score Supplementary Table 9 . Hazard ratios (HRs) and 95% CIs for developing one or more islet autoantibodies, multiple islet autoantibodies and diabetes in FDR children (FDR mother vs FDR father vs FDR sibling vs FDR multiplex), adjusted for sex, genetic factors (reference: DR4-DQ8/DR4-DQ8), and country (reference US) 
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Haplotype ID DR3/4-DQ8 DR4-DQ8/ DR4-DQ8
G A G A G A A G G A A T A A A A C A A A C G A A C G A C G T C A G T 18.12 18.70 25 G G G G A G G G G A A T A A G T A G A G A G G G G A A C G A A C A A 15.14 14.62 28 G G G G A G G G G A A T A A G T A G T G A A G G G A A C G T A C A A 12.48 12.226 G G G G A G G G G A A T A A G T A G A G A G G G G A A C G T A C A A 9.86 3.56 12 G G G A G A A A A A A T A A A A C A A A C G A A C G A C G T C A A T 0.60 0.027 G G G G A G G G G A A T A A G T A G A G A G G G G G A C G T A C A A 0.31 0.27 16 G G G A G A A G G A A T A A A A C A A A C G A A C G A C G T C A A T 0.26 0.07 5 A G A G G G A G G G C A G G A A A A A A C G A G C G G A A T A C A T 0.15 0.10 21 G G G A G A A G G G C A G G A A A A A A C G A G C G G A A T A C A T 0.00.03 4 A G A G G G A G G G C A G G A A A A A A C G A A C G A C G T C A A T 0.05 0.03 23 G G G G A G G G G A A T A A A T A G A G A G G G G A A C G T A C A A 0.00 0.07 3 A G A G G G A G G A A A G G G A C G A G C G A G C G A A A T A A A T 0.03 0.00 8 G A G A G A A G G A A T A A A A C A A A C G A A C G A C G T C A A T 0.03 0.00 13 G G G A G A A A A A A T G G A A A A A A C G A G C G G A A T A C A T 0.02 0.00 17 G G G A G A A G G A A T A A A A C A A A C G A A C G A C G T C A G T 0.00 0.00 1 A A A G G G A G G G C A G G A A A A A A C G A G C G G A A T A C A T 0.02 0.00 6 A G G G G G A G G G A A G G G A C G A A A G A G C G G C A T A A A T 0.00 0.02 10 G A G A G A A G G A A T G G A A A A T A C A A G C G G A A T A C A T 0.02 0.00 11 G A G G A G G G G A A T A A G T A G T G A A G G G A A C G T A C A A 0.00 0.00 14 G G G A G A A A G A A T A A A A C A A A C G A A C G A C G T C A G T 0.00 0.00 15 G G G A G A A G A A A T A A A A C A A A C G A A C G A C G T C A A T 0.00 0.02 24 G G G G A G G G G A A T A A G T A G A G A G G G G A A C A T A C A A 0.00 0.00 x G A G A G A A G G A A T G G A A A A A A C G A G C G G A A T A C A T 0.00 0.00 x G G G A G A A G G G C A G G A A A A T A C A A G C A G A A T A C A T
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